secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2022-09-22T23:59:59+00:00
Accession:  0001628280-22-025349
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncology Institute appoints Mark Pacala and Gabe Ling to Board, expanding to 9 members
--------------------------------------------------------------------------------

- Mark Pacala brings >30 yrs healthcare management/PE experience; former CEO of Forum Group and American Whole Health.
- Gabe Ling is co-founder of M33 Growth, a principal stockholder; previously partner at General Catalyst.
- Appointments effective immediately; new directors will serve until 2023 Annual Meeting.
- Neither director will serve on any committee; Pacala determined independent; Ling affiliated with M33.
- Compensation will follow standard non-employee director policy as disclosed in 10-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000162828022025349/0001628280-22-025349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000162828022025349/toi-20220921.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-025349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer